Skip to content

Clinical Observation of Intense Pulsed Light immediate Compound Acid Peeling in the Treatment of Melasma:A Split-face Study

Clinical Observation of Intense Pulsed Light immediate Compound Acid Peeling in the Treatment of Melasma:A Split-face Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106076
Enrollment
Unknown
Registered
2025-07-17
Start date
2021-03-08
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma

Interventions

combined side:Immediate intense pulse light therapy after compound acid peeling
control side:Intense pulse light therapy

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Age range from 18 to 60 years old, regardless of gender; (2) Conform to the diagnostic criteria of Melasma, the face must have light brown to dark brown patches with clear boundaries, no inflammatory manifestations and scales, and exclude pigmentation caused by other diseases, which can be combined with other features; (3) It was diagnosed as epidermal, dermal or mixed Melasma by Wood lamp; (4) Fitzpatrick skin classification 3/4; (5) Those who can persist in completing treatment and have not used other methods of treatment during the follow-up period; (6) The participants voluntarily participate and need to sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Pregnant and lactating women; (2) Severe heart, liver, and kidney dysfunction; (3) Used other freckle removing products and drugs, chemical exfoliation, laser and other treatment methods within 1 month; (4) Have taken isotretinoic acid or oral contraceptives within one month; (5) Facial maceration, ulceration, erosion, recurrent herpes infection; (6) Acne vulgaris or active facial dermatitis, sensitive skin; (7) Have a history of hypertrophic scar or Keloid; (8) Unable to persist in treatment and avoid excessive exposure to sunlight; (9) Mental disorders or severe systemic diseases.

Design outcomes

Primary

MeasureTime frame
mMASI;Skin melanin index;Skin erythema index;VISIA score;

Countries

China

Contacts

Public ContactYan Wu

the First Hospital of China Medical University

jlwuyan@126.com+86 158 4021 3656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026